These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9724557)

  • 1. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus.
    Newman RA; Chen W; Madden TL
    J Pharm Sci; 1998 Sep; 87(9):1077-80. PubMed ID: 9724557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
    Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
    HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
    Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
    Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).
    Zembower DE; Liao S; Flavin MT; Xu ZQ; Stup TL; Buckheit RW; Khilevich A; Mar AA; Sheinkman AK
    J Med Chem; 1997 Mar; 40(6):1005-17. PubMed ID: 9083491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B.
    Galinis DL; Fuller RW; McKee TC; Cardellina JH; Gulakowski RJ; McMahon JB; Boyd MR
    J Med Chem; 1996 Oct; 39(22):4507-10. PubMed ID: 8893846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human.
    Xu ZQ; Norris KJ; Weinberg DS; Kardatzke J; Wertz P; Frank P; Flavin MT
    J Chromatogr B Biomed Sci Appl; 2000 Jun; 742(2):267-75. PubMed ID: 10901131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
    Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical library and structure-activity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents.
    Ma T; Liu L; Xue H; Li L; Han C; Wang L; Chen Z; Liu G
    J Med Chem; 2008 Mar; 51(5):1432-46. PubMed ID: 18284187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-HIV activities of HIV-1 reverse transcriptase inhibitor racemic 11-demethyl-calanolide A].
    Peng ZG; Chen HS; Wang L; Liu G
    Yao Xue Xue Bao; 2008 May; 43(5):456-60. PubMed ID: 18717330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
    Currens MJ; Mariner JM; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.
    Zhou XJ; Garner RC; Nicholson S; Kissling CJ; Mayers D
    J Clin Pharmacol; 2009 Dec; 49(12):1408-16. PubMed ID: 19776293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
    Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
    Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis.
    Xu ZQ; Barrow WW; Suling WJ; Westbrook L; Barrow E; Lin YM; Flavin MT
    Bioorg Med Chem; 2004 Mar; 12(5):1199-207. PubMed ID: 14980631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
    Budihas SR; Gorshkova I; Gaidamakov S; Wamiru A; Bona MK; Parniak MA; Crouch RJ; McMahon JB; Beutler JA; Le Grice SF
    Nucleic Acids Res; 2005; 33(4):1249-56. PubMed ID: 15741178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyranocoumarins from tropical species of the genus Calophyllum: a chemotaxonomic study of extracts in the National Cancer Institute collection.
    McKee TC; Covington CD; Fuller RW; Bokesch HR; Young S; Cardellina II JH; Kadushin MR; Soejarto DD; Stevens PF; Cragg GM; Boyd MR
    J Nat Prod; 1998 Oct; 61(10):1252-6. PubMed ID: 9784162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor.
    Hanna L
    BETA; 1999 Apr; 12(2):8-9. PubMed ID: 11366704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
    Flavin MT; Rizzo JD; Khilevich A; Kucherenko A; Sheinkman AK; Vilaychack V; Lin L; Chen W; Greenwood EM; Pengsuparp T; Pezzuto JM; Hughes SH; Flavin TM; Cibulski M; Boulanger WA; Shone RL; Xu ZQ
    J Med Chem; 1996 Mar; 39(6):1303-13. PubMed ID: 8632437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens.
    Abu-Basha EA; Gehring R; Albwa'neh SJ
    J Vet Pharmacol Ther; 2007 Apr; 30(2):139-44. PubMed ID: 17348899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
    Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
    J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.